1776112-90-3 ((Mavelertinib)

Mavelertinib;YXX2180047;N-((3R,4R)-4-fluoro-1-(6-((3-methoxy-1-methyl-1H-pyrazol-4-yl)amino)-9-methyl-9H-purin-2-yl)pyrrolidin-3-yl)acrylamide;PF06747775;Mavelertinib [USAN];GTPL9765;JYIUNVOCEFIUIU-GHMZBOCLSA-N;SB19002;compound 21 [PMID: 28287730];N-[(3R,4R)-4-fluoro-1-[6-[(3-methoxy-1-methylpyrazol-4-yl)amino]-9-methylpurin-2-yl]pyrrolid;PF-06747775;N-[(3R,4R)-4-Fluoro-1-[6-[(3-methoxy-1-methyl-1H-pyrazol-4-yl)amino]-9-methyl-9H-purin-2-yl]-3-pyrrolidinyl]-2-propenamide;N-[(3R,4R)-4-Fluoro-1-[6-[(3-methoxy-1-methyl-1H-pyrazol-4-yl)amino]-9-methyl-9H-purin-2-yl]pyrrolidin-3-yl]acrylamide;Egfr T790M inhibitor PF-06747775;MAVELERTINIB [WHO-DD];N-((3R,4R)-4-FLUORO-1-(6-((3-METHOXY-1-METHYL-PYRAZOL-4-YL)AMINO)-9-METHYL-PURIN-2-YL)PYRROLIDIN-3-YL)PROP-2-ENAMIDE;PF-06747775, >=98% (HPLC);N-((3R,4R)-4-fluoro-1-(6-((3-methoxy-1-methyl-1H-pyrazol -4-yl)amino)-9-methyl-9H-purin-2-yl)pyrrolidin-3-yl)acrylamide;N-[(3R,4R)-4-FLUORO-1-{6-[(3-METHOXY-1-METHYLPYRAZOL-4-YL)AMINO]-9-METHYLPURIN-2-YL}PYRROLIDIN-3-YL]PROP-2-ENAMIDE;EX-A4999;SCHEMBL16714537;CS-0012907;C92352;N-[(3R,4R)-4-fluoro-1-[6-[(3-methoxy-1-methylpyrazol-4-yl)amino]-9-methylpurin-2-yl]pyrrolidin-3-yl]prop-2-enamide;Mavelertinib (USAN/INN);NSC788365;AC-33593;1776112-90-3;NSC-788365;UNII-YXX2180047;2-Propenamide, N-[(3R,4R)-4-fluoro-1-[6-[(3-methoxy-1-methyl-1H-pyrazol-4-yl)amino]-9-methyl-9H-purin-2-yl]-3-pyrrolidinyl]-;2-Propenamide, N-((3R,4R)-4-fluoro-1-(6-((3-methoxy-1-methyl-1H-pyrazol-4-yl)amino)-9-methyl-9H-purin-2-yl)-3-pyrrolidinyl)-;MS-27202;MAVELERTINIB [INN];D11368;CHEMBL3989970;DA-66623;AKOS032945529;HY-12972;BDBM50450870;

JYIUNVOCEFIUIU-GHMZBOCLSA-N

1S/C18H22FN9O2/c1-5-13(29)21-11-8-28(6-10(11)19)18-23-15(14-16(24-18)26(2)9-20-14)22-12-7-27(3)25-17(12)30-4/h5,7,9-11H,1,6,8H2,2-4H3,(H,21,29)(H,22,23,24)/t10-,11-/m1/s1

F[C@@H]1CN(C2N=C(C3=C(N(C)C=N3)N=2)NC2C(=NN(C)C=2)OC)C[C@H]1NC(C=C)=O